Skip to main content
SpringerLink
Log in

Does tumor grade influence the rate of lymph node metastasis in apparent early stage ovarian cancer?

Archives of Gynecology and Obstetrics volume 298, pages 179–182 (2018)Cite this article

Abstract

Purpose

To evaluate the prevalence of regional lymph node (LN) metastasis in patients with non-clear cell epithelial ovarian cancer apparently confined to the ovary, stratified by tumor grade.

Methods

The National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) database was accessed (1988–2014). We identified patients with epithelial ovarian carcinoma of serous, endometrioid and mucinous histology apparently confined to the ovary who underwent extensive lymphadenectomy (defined as at least 20 lymph nodes removed). Demographics, tumor histology, grade and lymph node status were collected. Comparisons were made with Chi square and Mann–Whitney U tests.

Results

A total of 1242 women met the inclusion criteria. Endometrioid adenocarcinoma was the most common histology (564 patients (45.4%)) while 443 (35.7%) and 235 (18.9%) patients had serous, and mucinous adenocarcinoma, respectively. The rate of LN metastasis in low-grade serous was 9.0% (6/67) vs. 14.4% (54/376) in high-grade serous histology (OR, 1.71, 95% CI 0.70, 4.14, p = 0.24). In patients with low-grade endometrioid tumors, the rate of LN metastasis was 1.7% (7/407) vs. 5.1% (8/157) observed in those with high-grade tumors (OR: 3.07, 95% CI 1.09, 8.61, p = 0.033). Lastly, the rate of LN metastasis in mucinous histology was 1.7% (3/177) in low-grade vs. 8.6% (5/58) in high-grade tumors (OR: 5.47, 95% CI 1.27, 23.66, p = 0.024).

Conclusions

Regional LN metastasis in apparent stage I low-grade mucinous and endometrioid ovarian tumors is infrequent.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

USD 39.95

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Fig. 1

References

  1. Siegel RL, Miller KD, Jemal A (2015) Cancer statistics, 2015. CA Cancer J Clin 65:5–29. https://doi.org/10.3322/caac.21314

    Article  Google Scholar 

  2. Young RC (2003) Early-stage ovarian cancer: to treat or not to treat. J Natl Cancer Inst 95(2):94–95

    Article  CAS  Google Scholar 

  3. Winter-Roach BA, Kitchener HC, Dickinson HO (2009) Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD004706.pub3

    Article  PubMed  Google Scholar 

  4. Kleppe M, Wang T, Van Gorp T et al (2011) Lymph node metastasis in stages I and II ovarian cancer: a review. Gynecol Oncol 123(3):610–614

    Article  CAS  Google Scholar 

  5. Surveillance, Epidemiology, and End Results (SEER) Program Research Data (1973–2015), National Cancer Institute, DCCPS, Surveillance Research Program. https://www.seer.cancer.gov

  6. Cancer Incidence in Five Continents Vol.X IARC Scientific Publication No 164, 2014 Chapter 4, p84

  7. Gockley A, Melamed A, Bregar AJ, Clemmer JT, Birrer M, Schorge JO, Del Carmen MG, Rauh-Hain JA (2017) Outcomes of women with high-grade and low-grade advanced-stage serous epithelial ovarian cancer. Obstet Gynecol 129(3):439–447

    Article  Google Scholar 

  8. Lago V, Minig L, Fotopoulou C (2016) Incidence of lymph node metastases in apparent early-stage low-grade epithelial ovarian cancer: a comprehensive review. Int J Gynecol Cancer. 26(8):1407–1414

    Article  Google Scholar 

  9. Minig L, Heitz F, Cibula D et al (2017) Patterns of lymph node metastases in apparent stage i low-grade epithelial ovarian cancer: a multicenter study. Ann Surg Oncol 24(9):2720–2726

    Article  Google Scholar 

  10. Kaldawy A, Segev Y, Lavie O, Auslender R, Sopik V, Narod SA (2016) Low-grade serous ovarian cancer: a review. Gynecol Oncol 143(2):433–438

    Article  Google Scholar 

  11. Nasioudis D, Chapman-Davis E, Witkin SS et al (2017) Prognostic significance of lymphadenectomy and prevalence of lymph node metastasis in clinically-apparent stage I endometrioid and mucinous ovarian carcinoma. Gynecol Oncol 144(2):414–419

    Article  Google Scholar 

Download references

Funding

The authors declare no source of funding for the research conducted.

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, Hospital of the University of Pennsylvania, Helen O’Dickens Women’s Health Center, 3400 Spruce Street, Philadelphia, PA, USA

    Dimitrios Nasioudis, Spyridon A. Mastroyannis, Emily M. Ko & Nawar A. Latif

Authors
  1. Dimitrios Nasioudis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Spyridon A. Mastroyannis
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Emily M. Ko
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Nawar A. Latif
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

DN: Conception, Protocol/project development, Data collection and management, Data analysis, Manuscript writing/editing, SAM: Data analysis, Manuscript writing/editing, EMK: Data analysis, Manuscript writing/editing, NAL: Protocol/project development, Data analysis, Manuscript writing/editing.

Corresponding author

Correspondence to Dimitrios Nasioudis.

Ethics declarations

Conflict of interest

All authors declare no potential conflict of interest, including and financial or personal relationship which could viewed as one.

Ethical standards

The SEER is a public dataset available to the public for research purpose. All patient data are de-identified. The present study was deemed exempt by the institutional review board.

Rights and permissions

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nasioudis, D., Mastroyannis, S.A., Ko, E.M. et al. Does tumor grade influence the rate of lymph node metastasis in apparent early stage ovarian cancer?. Arch Gynecol Obstet 298, 179–182 (2018). https://doi.org/10.1007/s00404-018-4789-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00404-018-4789-2

Keywords

search

Navigation